Scandinavian ChemoTech AB Series B (CMOTEC-B) - Total Assets
Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) holds total assets worth Skr11.11 Million SEK (≈ $1.20 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Scandinavian ChemoTech AB Series B (CMOTEC-B) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Scandinavian ChemoTech AB Series B - Total Assets Trend (2013–2025)
This chart illustrates how Scandinavian ChemoTech AB Series B's total assets have evolved over time, based on quarterly financial data. See net assets of Scandinavian ChemoTech AB Series B for net asset value and shareholders' equity analysis.
Scandinavian ChemoTech AB Series B - Asset Composition Analysis
Current Asset Composition (December 2025)
Scandinavian ChemoTech AB Series B's total assets of Skr11.11 Million consist of 69.2% current assets and 30.8% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 27.8% |
| Accounts Receivable | Skr2.68 Million | 20.3% |
| Inventory | Skr2.79 Million | 21.2% |
| Property, Plant & Equipment | Skr119.00K | 0.9% |
| Intangible Assets | Skr3.79 Million | 28.7% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Scandinavian ChemoTech AB Series B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Scandinavian ChemoTech AB Series B market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scandinavian ChemoTech AB Series B's current assets represent 69.2% of total assets in 2025, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 27.8% of total assets in 2025, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 28.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 28.7% of total assets.
Scandinavian ChemoTech AB Series B Competitors by Total Assets
Key competitors of Scandinavian ChemoTech AB Series B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $260.53 Million |
Scandinavian ChemoTech AB Series B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.79 | 0.85 | 1.80 |
| Quick Ratio | 0.46 | 0.47 | 1.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-1.99 Million | Skr-1.42 Million | Skr2.90 Million |
Scandinavian ChemoTech AB Series B - Advanced Valuation Insights
This section examines the relationship between Scandinavian ChemoTech AB Series B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 57.33 |
| Latest Market Cap to Assets Ratio | 0.62 |
| Asset Growth Rate (YoY) | -1.3% |
| Total Assets | Skr13.20 Million |
| Market Capitalization | $8.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scandinavian ChemoTech AB Series B's assets below their book value (0.62x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Scandinavian ChemoTech AB Series B's assets decreased by 1.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Scandinavian ChemoTech AB Series B (2013–2025)
The table below shows the annual total assets of Scandinavian ChemoTech AB Series B from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr13.20 Million ≈ $1.42 Million |
-1.35% |
| 2024-12-31 | Skr13.38 Million ≈ $1.44 Million |
-10.01% |
| 2023-12-31 | Skr14.87 Million ≈ $1.60 Million |
-31.48% |
| 2022-12-31 | Skr21.70 Million ≈ $2.34 Million |
-15.92% |
| 2021-12-31 | Skr25.81 Million ≈ $2.78 Million |
+61.40% |
| 2020-12-31 | Skr15.99 Million ≈ $1.72 Million |
-8.57% |
| 2019-12-31 | Skr17.49 Million ≈ $1.88 Million |
-23.32% |
| 2018-12-31 | Skr22.81 Million ≈ $2.45 Million |
+77.58% |
| 2017-12-31 | Skr12.84 Million ≈ $1.38 Million |
-23.67% |
| 2016-12-31 | Skr16.83 Million ≈ $1.81 Million |
+152.93% |
| 2015-12-31 | Skr6.65 Million ≈ $715.95K |
+9995.57% |
| 2014-12-31 | Skr65.90K ≈ $7.09K |
+48.40% |
| 2013-12-31 | Skr44.41K ≈ $4.78K |
-- |
About Scandinavian ChemoTech AB Series B
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian Che… Read more